The CyTuVax depot-attached cytokine technology is protected by patent "Composition comprising cytokine macro-aggregates" PCT/EP2013/072865. The patent received an excellent evaluation report from the International Examining Authority of the European Patent Office in July 2014, stating no objections on all the 17 claims for novelty, inventive steps and industrial applicability. In May 2015, the patent has been approved by EPO.
CyTuVax’s vaccination technology is further protected by proprietary methods for adjuvant manufacturing (cytokine-depot binding).